The issue opens with a special report on PwC's recent acquisition of PRTM consulting and an outline of the opportunities our new combined team can bring to clients within the AsiaPac region.
In our compliance section we have included further information on Chinese steps regarding the manufacturing of medicines and actions by Singapore to avert the potential threat of counterfeit products. While our Regulatory section reports on new proposed limits on Foreign Direct Investment in India.
Find out more about the push for creating a more affordable market of pharmaceuticals in the Asia Pacific in our pricing section- a growing theme within many markets within the region. And read about the latest news from multiple territories in the tax section covering R&D credits, various tax incentives, new deductions for acquired IP and Transfer Pricing developments.